Fresolimumab and Stereotactic Ablative Radiotherapy in Early Stage Non-small Cell Lung Cancer

Trial Profile

Fresolimumab and Stereotactic Ablative Radiotherapy in Early Stage Non-small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs Fresolimumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SABR-ATAC
  • Most Recent Events

    • 26 Sep 2016 Planned primary completion date changed from 1 May 2019 to 1 Jan 2020.
    • 13 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 26 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top